36 results about "Enation" patented technology

The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in their genome. The invention uses a Drosophila melanogaster expression system to provide high yields of recombinant subunit proteins with native-like conformation.

The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in their genome. The invention uses a Drosophila melanogaster expression system to provide high yields of recombinant subunit proteins with native-like conformation.

Provided are methods for diagnosing sporadic and familial forms of amyotrophic lateral sclerosis (“ALS”) that detect conformers or conformer patterns of the copper-zinc superoxide dismutase-1 (“SOD-1”) enzyme that are common to sporadic or familial ALS individuals but distinct from SOD-1 conformers of normal individuals. Methods of identifying candidate drugs that modulate SOD-1 conformer formation also are provided.

Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production conformational antibodies against both L1 proteins upon administration to mice.

The invention relates to a single strand conformation polymorphism (SSCP) marker closely linked with a major wheat scab resistance quantitative trait locus (QTL). The SSCP marker is characterized in that: scab resistance candidate genes of a scab resistance QTL in a 3BS area of a wheat variety or strain resisting scab is PCR amplified by using a primer; after denaturalization, a PCR-amplified product has different single strand conformation; and the SSCP marker closely linked with the major wheat scab resistance QTL is established for detecting a genotype of the wheat variety or strain during breeding. The SSCP marker has the advantages of: overcoming the disadvantages that the wheat scab resistance screening can only be authenticated in a flowering period and is easily influenced by the environment in conventional breeding, predicting and screening wheat plants with the scab resistance by detecting a molecular marker at a seedling stage, eliminating disease plants, reducing waste of labor and materials and improving the breeding efficiency. Compared with an ABI DNA sequence analysis meter-based marker, the SSCP marker closely linked with the major wheat scab resistance QTL has the advantages of simple and convenient operation, low cost and same sensitivity.

The inventive subject matter relates to an immunogenic composition composed of a chimeric molecule including a conformationally stable adhesin from Escherichia coli fused to a bacterial toxin A subunit, such as cholera toxin A subunit or heat-labile Escherichia coli toxin A subunit. The invention also relates to the adhesin-toxin chimera noncovalently associated with a toxin B subunit of the same or different species as the A subunit. The invention also relates to a method of utilizing an adhesin / toxin fusion composition to elicit an immune response.

A glycoprotein E2 of classical swine fever virus (CSFV) expressed in a recombinant yeast system. The recombinant E2 protein (yE2) is able to form a homodimer, exhibits glycosylation conformation and possesses correct immunogenicity. An anti-CSFV vaccine can be provided with yE2 as a major active ingredient to induce high titers of neutralizing antibody in vaccinated pigs, and to induce a protection against CSFV infection.

The invention relates to monoclonal antibody against hemagglutinin of influenza A H1N1 virus. The invention further provides a hybridoma cell strain secreting the monoclonal antibody. The invention further provides a kit containing the monoclonal antibody. With the present invention, the monoclonal antibody combines with conformational epitope of the hemagglutinin of the influenza A H1N1 virus; the monoclonal antibody has high affinity with a HA1 fragment of the hemagglutinin of the influenza A H1N1 virus; the monoclonal antibody does not generate cross reactions with other proteins; the monoclonal antibody has very high specificity and sensitivity.

Provided is a crystal of a florigen activation complex, including a florigen, a 14-3-3 protein, and a bZIP transcription factor bound to each other. In addition, flowering of a plant is regulated by controlling mechanisms of interactions among those proteins utilizing the crystal. These are achieved as follows. With attention focused on the fact that Hd3a is bound to FD1 via GF14c to form a florigen activation complex, a crystal of the florigen activation complex is produced, conformational information is obtained through the use of the crystal of the florigen activation complex, and the flowering of a plant is regulated by controlling mechanisms of interactions among the florigen and the like utilizing such conformational information.

More than 90% of mutations found in the p53 protein produce a conformational change in p53 which results in the exposure of an epitope, which is otherwise hidden in the hydrophobic core of the molecule. A single chain antibody (scFv) which specifically recognizes this common mutant epitope in mutant p53 but not in wild type p53 is disclosed. Also described are a DNA molecule encoding the scFv, pharmaceutical compositions comprising the antibody and methods of treatment using the pharmaceutical compositions.

The invention belongs to the research and development field of neuro-protective medicament, and discloses a traditional Chinese medicine monomer capable of promoting growth of motoneuron. In the aspect of isolated cell level, the traditional Chinese medicine compound, can obviously promote enation of motoneuron; in the aspect of integral animal level, the compound can obviously promote functional rehabilitation of impaired sciatic nerve and femoral nerve. The invention can be applied to medicinal development for amyotrophic lateral sclerosis and relevant motoneuro symptoms.

The invention relates to polypeptide biological technical field, which discloses a spatial conformation mimic antigen epitope of H3-type influenza virus hemagglutinin, and relative application. The sequence of the spatial conformation mimic antigen epitope is SEQ ID No. 1. The invention utilizes anti-recombination HA1 rabbit serum IgG selection phage 12 peptide library, uses phage ELISA, DNA sequencing, western bolt, and software analysis to analyze selected colony, and selects the small peptide from random phage 12 peptide library, which can be specially combined with anti-recombination HA1 rabbit serum IgG. The inventive spatial conformation mimic antigen epitope can prepare diagnostic reagent box of H3-type influenza virus.

An objective of the present invention is to provide methods for accumulating in rice seeds a partial peptide of a mite antigen protein comprising several T cell epitopes, or a mite antigen peptide that has been modified to not form a conformation to be recognized as an antigen, and plants which have accumulated these peptides.To achieve the above objective, the present inventors have tried to generate seeds (rice) of rice plants that have accumulated mite antigen peptide variants. As a result, the present inventors developed genetically modified rice plants which express and accumulate these mite antigen peptide variants, and demonstrated their effect on asthma, in particular, by orally feeding mice with these variants to induce immunological tolerance, thereby completing the present invention.

The invention relates to a construction method of Escherichia coli cold shock assistant dissolving type expression plasmids, and a method for preparing a water-soluble heterogenous polypeptide by applying the Escherichia coli cold shock assistant dissolving type expression plasmid. The cold shock assistant dissolving type expression plasmids for realizing small ubiquitin modified protein (SUMO) and exogenous gene fusion expression under the control of a promoter of a cold shock gene is constructed by using a seamless cloning technology. A chimeric cysteine desulfurase is cloned into the plasmids, such as widely-known pCold I and PET28 series plasmids, to obviously improve the water solubility, the stability and the enzyme activity of recombinant proteins. The SUMO has no influences on thetarget protein space conformation of widely-known pCold TF plasmids. The cutting efficiency of an SUMO label is more than 95% when enzyme digestion is performed at 25 DEG C for 1 h according to a ratio of Ulp1 protease to the recombinant protein of 1 U : (0.5-1) mg, so the Escherichia coli cold shock assistant dissolving type expression plasmids are very suitable for preparing proteins having natural N ends in the fields of bioengineering pharmacy and structural biology.

The group-B type-III coxsackie virus gene vaccine is one kind of vaccine for preventing coxsackie virus infection. The present invention aims at providing CVB3 virus gene vaccine as one kind of pcCVP4-CVB1VP1 plasmid comprising VP1 gene with CVB3 coding main neutral antigen and plasmid pCEP4 as eukaryotic expression vector. Compared with traditional vaccines, the gene vaccine of the present invention has the following advantages: direct DNA inoculation without complicated antigen preparing and purifying process, integrated and lasting immune response with antigen polypeptide submission similar to that in natural infection and no antigen epitope altering, common physical and chemical characteristics with capability of embedding several destination genes in the identical plasmid to form combined vaccine, simple preparation process with low cost and high safety and stability for easy storing and transportation.

The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.

The invention relates to an anti-influenza-virus broad-spectrum-neutrality neutralizing molecule 3E1 capable of neutralizing multiple influenza virus subtypes. The functions of the antibody provided by the invention are determined by specific gene sequences of genes in light chain and heavy chain variable regions; and the antibody can be combined with HA2 subunit of influenza virus hemagglutinin (HA) with native conformation, and can prevent multiple influenza virus subtypes from infecting permissive cells. By utilizing the variable region genes or complementary determining region (CDR) genes, different forms of gene engineering antibodies can be modified and produced in any expression system using prokaryotic and eukaryotic cells.

The present invention relates to a non-toxic clostridium perfringens beta-toxin genetic engineering vaccine. The prepared clostridium perfringens beta-toxin recombinant subunit vaccine is produced bycodon-optimized production and multiple-amino-acid-mutation- containing recombinant clostridium perfringens beta-toxin proteins, thus maximally retains integrity and spatial conformation of natural toxin proteins, keeps immunogenicity, and also avoids biosafety hazards brought by single amino acid mutations. The vaccine also has advantages of simple preparation technology, low immune dose, excellent vaccine efficacy, etc., greatly reduces biosafety risks in vaccine production processes compared with current commercial clostridium perfringens natural toxin inactivated vaccines in China, and isan ideal candidate vaccine for upgrading of current type B and type C clostridium perfringens toxin vaccines in China; and when the vaccine and other antigens are commonly used to prepare a combined vaccine, dose of the combined vaccine cannot be increased and the combined vaccine can be prepared.

The group-B type-II coxsackie virus gene vaccine is one kind of vaccine for preventing coxsackie virus infection. The present invention aims at providing group-B type-II coxsackie virus gene vaccine as one kind of pcDNA3-CVB2VP1 eukaryotic expression plasmid comprising eukaryotic expression system pcDNA3 and CVB2VP1 gene. The gene vaccine of the present invention has the following advantages: direct DNA inoculation without complicated antigen preparing and purifying process, integrated and lasting immune response with antigen polypeptide submission similar to that in natural infection and no antigen epitope altering, common physical and chemical characteristics with capability of embedding several destination genes in the identical plasmid to form combined vaccine, simple preparation process with low cost and high safety and stability for easy storing and transportation.

The invention discloses a device for improving the yield per unit of beautiful millettia roots. The device structurally comprises a yield improving maintenance device, a sheath, a fastening plate, a hinge and a protection plate. The device has the advantages that a stem protection sleeve and an enation frame are matched each other, so that rhizome growth of the beautiful millettia roots at the seedling stage is corrected and fixed, rhizome fracture is prevented, standard enation climbing of the beautiful millettia roots is implemented through a rectangular telescopic frame, sunshine obstruction of the beautiful millettia roots caused by overlapping or deviation development of the beautiful millettia roots is avoided, a net plate and a weed pulling mechanism are matched with each other, nutrients in the unit area of the beautiful millettia roots cannot be lost, weeds scrambling for the nutrients of the beautiful millettia roots are effectively removed, so that the yield per unit of thebeautiful millettia roots is effectively improved, the protection plate is adjustable, trapezoid-shaped trenches in the planting position of the beautiful millettia roots are effectively strengthened,and reduction of the survival rate of the beautiful millettia roots caused by falling and loss of soil in raining or irrigating is avoided.

The group-B type-I coxsackie virus gene vaccine is one kind of vaccine for preventing coxsackie virus infection. The present invention aims at providing CVB1 virus gene vaccine as one kind of pcCEP4-CVB1VP1 plasmid comprising VP1 gene with CVB1 coding main neutral antigen and plasmid pCEP4 as eukaryotic expression vector. Compared with traditional vaccines, the gene vaccine of the present invention has the following advantages: direct DNA inoculation without complicated antigen preparing and purifying process, integrated and lasting immune response with antigen polypeptide submission similar to that in natural infection and no antigen epitope altering, common physical and chemical characteristics with capability of embedding several destination genes in the identical plasmid to form combined vaccine, simple preparation process with low cost and high safety and stability for easy storing and transportation.